A Study of BPI-452080 in Subjects With Solid Tumors
This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors
Solid Tumor|Renal Cell Carcinoma|Von Hippel-Lindau Disease
DRUG: BPI-452080
adverse events (AEs), Safety and tolerability will be assessed by monitoring frequency, duration and severity of adverse events, Through the Phase I, approximately 24 months
Cmax, Maximum observed concentration, Through the Phase I, approximately 24 months|Tmax, Time to reach maximum observed plasma concentration, Through the Phase I, approximately 24 months|t1/2, Half-life time, Through the Phase I, approximately 24 months|the objective response rate（ORR）, The proportion of patients with complete response (CR) and partial response (PR) in all patients, Through the Phase I, approximately 24 months|Progression free survival (PFS), The time from the date of randomization to disease progression (PD) or death, whichever occurs first, Through the Phase I, approximately 24 months
This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors